1428155-06-9

Upstream product

• 7306-68-5 6-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine 
• 13331-27-6 m-nitrobenzene boronic acid 
• 87-42-3 6-chloropurine 
• 110-87-2 3,4-dihydro-2H-pyran 

Downstream Products

• 1428155-44-5 2-methoxy-N-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)phenyl)benzamide 
• 1428155-45-6 4-bromo-3-methyl-N-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)phenyl)benzamide 
• 1428155-46-7 2-fluoro-N-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)phenyl)benzamide 
• 1428155-47-8 2-fluoro-N-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)phenyl)pyridine-3-carboxamide 
• 1428155-48-9 2-methoxy-N-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)phenyl)pyridine-3-carboxamide 
• 1428155-49-0 1-(3-fluorophenyl)-2-oxo-N-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)phenyl)-1,2-dihydropyridine-3-carboxamide 
• 1428155-58-1 C₂₃H₁₅FN₆O₂ 
• 1428155-50-3 1-(4-fluorophenyl)-2-oxo-N-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)phenyl)-1,2-dihydropyridine-3-carboxamide 
• 1428155-59-2 C₂₃H₁₅FN₆O₂ 
• 1428155-51-4 2-oxo-N-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)phenyl)-1-(4-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide 
• 1428155-60-5 C₂₄H₁₅F₃N₆O₂ 
• 1428155-52-5 2-oxo-N-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)phenyl)-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide 
• 1428155-61-6 C₂₄H₁₅F₃N₆O₂ 
• 1428155-53-6 C₁₉H₁₅N₅O₂ 

Relevant academic research and scientific papers

N-substituted phenylacrylamide derivative and its preparation method and purpose

The invention relates to the field of chemical medicines and concretely relates to an N-substituted phenylacrylamide derivative and its preparation method and use. The invention provides the N-substituted phenylacrylamide derivative. The N-substituted phenylacrylamide derivative has a structure shown in the formula I. The invention also provides a preparation method and a use of the N-substituted phenylacrylamide derivative. The N-substituted phenylacrylamide derivative can selectively inhibit JAK3 and provide a novel choice for treating JAK3-related diseases such as rheumatoid arthritis, asthma, chronic obstructive pulmonary diseases and tumors.

Inhibitors of the TAM subfamily of tyrosine kinases: Synthesis and biological evaluation

The TAM subfamily of Receptor Tyrosine Kinases (RTKs) contains three human proteins of therapeutical interest, Axl, Mer, and Tyro3. Our goal was to design a type II inhibitor specific for this family, i.e. able to interact with the allosteric pocket and with the hinge region of the kinase. We report the synthesis of several series of purine analogues of BMS-777607. The structural diversity of the designed inhibitors was expected to modify the interactions formed in the binding site and consequently to modulate their selectivity profiles. The most potent inhibitor 6g exhibits Kds of 39, 42, 65 and 200 nM against Axl, Mer, Met and Tyro3 respectively. Analysis of the affinity of 6g for active and inactive forms of Abl1, an RTK protein that does not belong to the TAM subfamily, together with the binding modes of 6g predicted by docking studies, indicates that 6g displays some selectivity for the TAM family and may act as a type II inhibitor. Crown Copyright